188 publications
A paradigm shift in perception, learning and action - core of the second advice of the Committee Innovation Health Care Professions & Education
Translation of the core of the second advice of The Committee Innovation Health Care Professions & Education.
Netupitant - palonosetron (Akynzo) for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy
Zorginstituut Nederland has assessed the medicine netupitant/palonosetron (Akynzeo), whereby they came to the following...
A paradigm shift in perception, learning and action - summary of the second advice of the Committee Innovation Health Care Professions & Education
Summary of the second report of The Committee Innovation Health Care Professions & Education.
Eltrombopag (Revolade) in cases of severe aplastic anaemia
Zorginstituut Nederland has approved a pharmacotherapeutic report for the medicine eltrombopag (Revolade) in cases of severe...
Daclizumab (Zinbryta) for the treatment of relapsing (recidive) forms of multiple sclerosis (RMS)
Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta), whereby they came to the...
Fingolimod (Gilenya)
Zorginstituut Nederland has advised on amending the conditional inclusion of the medicine fingolimod (Gilenya) in the Medicines...
Future scenarios about drug development and drug pricing
This report is the result of a consultative and deliberative process — initiated by the Belgian Healthcare Knowledge Centre...
Guideline for economic evaluations in healthcare
This new Guideline unifies all previously available Dutch guidelines, links up with international developments, provides un...
Tranylcypromine (Tracydal) in patients with a severe multi-resistant depressive disorder
Zorginstituut Nederland carried out a budget impact analysis for the medicine tranylcypromine (Tracydal). They reached the...
Tolperison (Tolpermyo)
Zorginstituut Nederland has drawn up a pharmacotherapeutic report for the medicine tolperison (Tolpermyo), whereby it reached...